Identification of triazolam, etizolam and their metabolites in biological samples by liquid chromatography tandem mass spectrometry

Significance of the Topic

Benzodiazepine derivatives such as triazolam and etizolam are widely prescribed for their sedative, anxiolytic and muscle-relaxant properties. Their rapid metabolism and structural similarity among parent compounds and metabolites pose analytical challenges in clinical and forensic toxicology. A robust, selective analytical method is essential for accurate identification and quantification in biological fluids.

Objectives and Study Overview

This study aimed to develop and validate a high-resolution LC-MS/MS workflow for simultaneous detection of etizolam, triazolam and four primary metabolites (alpha-hydroxytriazolam, 4-hydroxytriazolam, alpha-hydroxyetizolam, 8-ethylhydroxyetizolam) in biological matrices. Key goals included optimizing chromatographic separation, maximizing mass spectrometric selectivity, and demonstrating applicability in in vitro metabolism assays.

Methodology and Instrumental Setup

In vitro metabolism was performed by incubating 40 μM of each parent drug with human liver S9 fraction, NADP+ regeneration system and cofactors at pH 7.4, 37 °C for ~18 hours. Post-incubation, samples were protein-precipitated with cold acetonitrile, centrifuged, dried, reconstituted in water and filtered (0.2 μm).

• Chromatography: Shimadzu Nexera UHPLC equipped with YMC-Triart C18 column (150 × 2 mm, 1.9 μm). Mobile phases: (A) 10 mM formic acid in water; (B) 10 mM formic acid/acetonitrile (1∶1). Gradient: 40% B at 0 min to 65% B at 40 min, returning to 40% B by 60 min; flow rate 0.3 mL/min; column at 40 °C; injection volume 1 μL.
• Mass Spectrometry: Shimadzu LCMS-8030 triple quadrupole, ESI positive mode, multiple reaction monitoring (MRM). A set of 12 quantitative and qualitative transitions was optimized for parent drugs and metabolites. MRM triggers automatic product ion scans for confirmation.

Results and Discussion

The optimized method achieved baseline separation of all six target analytes in a standard mix. Blank liver S9 extracts showed no interfering peaks, confirming high selectivity. In metabolized samples, three additional peaks were detected alongside the four expected metabolites; two were confirmed as alpha-hydroxyetizolam and 8-ethylhydroxyetizolam, while the third matched library spectra via triggered MS/MS scanning. Loop time was under one second, demonstrating rapid acquisition capability.

Benefits and Practical Applications

The developed workflow provides:

• High chromatographic resolution to distinguish closely related benzodiazepine metabolites.
• Enhanced specificity through MRM transitions combined with triggered MS/MS confirmation.
• Rapid throughput suitable for clinical and forensic screening laboratories.

Future Trends and Applications

Further developments may include high-resolution mass spectrometry (HRMS) for non-targeted screening, miniaturized sample preparation (e.g., microextraction), expansion to a broader spectrum of designer benzodiazepines, and integration of machine learning algorithms for automated spectral interpretation.

Conclusion

This study demonstrates that LC-MS/MS with small particle size column and MRM-triggered product ion scanning delivers a robust, sensitive and selective platform for simultaneous identification of triazolam, etizolam and their metabolites in biological matrices. The method is well suited for routine clinical and forensic toxicology applications.

References

• Matsui M., Minohata T., Shoji N., Kuriyama N., Yokoyama C., Matsumoto K., Watanabe J., Iida J. Identification of triazolam, etizolam and their metabolites in biological samples by liquid chromatography tandem mass spectrometry. IMSC 2012, PTh-196.